Back to top

Analyst Blog

Zacks Equity Research

Aegerion's Juxtapid Gets Pricing Authorization in Japan

SNY REGN AMGN

Trades from $3

Aegerion Pharmaceuticals, Inc. announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved the pricing authorization of its first product, Juxtapid. The product was approved in Japan in September for the treatment of homozygous familial hypercholesterolemia (HoFH). In Sep 2013, MLHW granted orphan drug status to Juxtapid.

Notably, HoFH is a rare genetic lipid disorder that impairs the function of the receptor responsible for removing LDL-C ("bad" cholesterol) from the body.

Juxtapid was launched in the U.S. in late Jan 2013, as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis where available, to reduce LDL cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B and non-high-density lipoprotein cholesterol (non-HDL-C) for the treatment of adult patients suffering from HoFH. In the U.S., the drug carries a boxed warning for the risk of hepatotoxicity.

Juxtapid gained EU approval under the trade name Lojuxta in Aug 2013.

Sales of Juxtapid declined 45.5% in the second quarter and 62.6% in the third quarter of 2016 from the year-ago levels due to a reduction in patients on therapy in the U.S., as a result of increased competition from PCSK9 inhibitors. The launch of Amgen, Inc.’s (AMGN - Free Report) Repatha and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) / Sanofi’s (SNY - Free Report) Praluent in the U.S. market dampened Juxtapid sales and will continue to do so in the forthcoming quarters.

In July, Aegerion announced plans to withdraw Juxtapid from the EU and certain other global markets by the end of 2016, unless it finds suitable partners as part of the company’s strategy to lower operating expenses, improve cash position amid stiff competition for Juxtapid, and increase cash generation from operations in 2017.

Aegerion currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>    


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

SANOFI-AVENTIS (SNY) - free report >>

REGENERON PHARM (REGN) - free report >>

AMGEN INC (AMGN) - free report >>